Umais Ahmed Shaikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Umais Ahmed Shaikh has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Aminath Waafira
The Maldives National University
1 shared publication - Ayesha Ejaz
Department of Medicine, King Edward Medical University, Lahore, Pakistan
1 shared publication - Fahad Amin
King Edward Medical University, Lahore, Pakistan
1 shared publication - Fatima Tu Zahra
King Edward Medical University, Neela Gumbad, Lahore, Pakistan
1 shared publication - Hadeel Shariq
Liaquat University of Medical and Health Sciences
1 shared publication - Huzaifa Nadeem
King Edward Medical University, Lahore, Pakistan
1 shared publication
Latest Publications
- 1 April 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (5) , 3265-3276
Platysma Closure vs. Nonclosure on Post-thyroidectomy Outcomes: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials
- 1 April 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (5) , 3265-3276
Platysma Closure vs. Nonclosure on Post-thyroidectomy Outcomes: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials
- Open Access
- 14 February 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2630512
Efficacy, immunogenicity, and safety of BCG revaccination against Mycobacterium tuberculosis: A systematic review and meta-analysis
Tuberculosis (TB) remains a leading global cause of death. While primary Bacillus Calmette-Guérin (BCG) vaccination offers protection in children, the role of BCG revaccination in adults remains unclear. This study evaluated the efficacy, immunogenicity, and safety of BCG revaccination against TB. A comprehensive literature search through July 2025, with independent data extraction by two reviewers. RevMan version 5.4 was used for analysis by applying random-effects models with 95% CIs. Six RCTs, involving 2400 participants, showed no significant effect of BCG revaccination on initial (RR 0.99) or sustained (RR 0.80) QFT conversion, showing only modest effectiveness against MTB. Immunogenicity evaluation showed a moderate increase in CD8+ T cell (p = .01) and cytokine-producing CD4+ T cell responses (p = .008). Safety analysis indicated increased adverse events, though a reduced risk of upper respiratory tract infections (RR 0.37) was noted. These results highlight a discrepancy between immune activation and quantifiable protection, suggesting limited BCG revaccination benefit in high-risk groups and the need for vaccines with proven protective immunity.
- 14 February 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2630512
Open AccessEfficacy, immunogenicity, and safety of BCG revaccination against Mycobacterium tuberculosis: A systematic review and meta-analysis
Tuberculosis (TB) remains a leading global cause of death. While primary Bacillus Calmette-Guérin (BCG) vaccination offers protection in children, the role of BCG revaccination in adults remains unclear. This study evaluated the efficacy, immunogenicity, and safety of BCG revaccination against TB. A comprehensive literature search through July 2025, with independent data extraction by two reviewers. RevMan version 5.4 was used for analysis by applying random-effects models with 95% CIs. Six RCTs, involving 2400 participants, showed no significant effect of BCG revaccination on initial (RR 0.99) or sustained (RR 0.80) QFT conversion, showing only modest effectiveness against MTB. Immunogenicity evaluation showed a moderate increase in CD8+ T cell (p = .01) and cytokine-producing CD4+ T cell responses (p = .008). Safety analysis indicated increased adverse events, though a reduced risk of upper respiratory tract infections (RR 0.37) was noted. These results highlight a discrepancy between immune activation and quantifiable protection, suggesting limited BCG revaccination benefit in high-risk groups and the need for vaccines with proven protective immunity.